HER2/c-erbB-2蛋白在胃癌组织中的表达及其临床意义

摘要

Objective To investigate the expression of epidermal growth factor receptor 2 (HER2/c-erbB-2) protein in gastric carcinoma tissue and normal gastric tissue, and to analyze its relationship with clinical parameters and survival time of patients. Methods Eighty-eight patients with gastric carcinoma who received operation therapy from Jan. 2012 to Oct. 2015 were selected as the research subjects. The expression of HER2/c-erbB-2 protein in the gastric cancer tissue (88 cases) and corresponding normal gastric tissue (26 cases) were evaluated by two step immunohisto-chemical (IHM) method. The relationships between the HER2/c-erbB-2 protein positive expression in gastric carcinoma and its clinicopathological characteristics such as age, gender, lymph node metastasis were analyzed. Results The HER2/c-erbB-2 protein was mainly expressed in the cell membrane, and a small part was expressed in the cytoplasm. The positive rate in carcinoma tissue was significantly higher than that in normal gastric tissue, 27.3%vs 3.8%, and the difference was statistically significant (P<0.05). The positive expression of HER2/c-erbB-2 was related to the depth of tumor invasion and regional lymph node metastasis (P<0.05). The median survival time of HER2/c-erbB-2 positive and negative patients were respectively 13.8 months and 33.9 months, and the difference was statistically significant between the two groups (HR=2.25, 95%CI:1.06~4.80, P<0.05). Conclusion HER2/c-erbB-2 protein may be related to occur-rence, development, and invasion and metastasis of gastric carcinoma, and can be used as a marker of poor prognosis.%目的：探讨表皮生长因子受体2(HER2/c-erbB-2)蛋白在胃癌患者癌组织、远癌正常胃组织中的表达及其与患者临床特征参数和生存期的关系。方法选取2012年1月至2015年10月上海交通大学医学院苏州九龙医院普外科手术治疗的88例胃癌患者为研究对象，采用IHM两步方法检测88例胃癌患者癌组织及26例部分配对远癌正常胃组织中HER2/c-erbB-2的表达情况。分析胃癌患者癌组织中HER2/c-erbB-2阳性表达与患者的年龄、性别、淋巴结转移等临床病理特征的关系；比较HER2/c-erbB-2阳性胃癌患者与阴性患者生存期有无差别。结果 HER2/c-erbB-2蛋白主要在胞膜中表达，少部分表达于细胞浆；HER2/c-erbB-2在癌及远癌组织中阳性率分别为27.3%和3.8%，癌组织显著高于远癌组织，差异有统计学意义(P<0.05)；HER2/c-erbB-2阳性表达与肿瘤的浸润深度和区域淋巴结转移有关(P<0.05)；HER2/c-erbB-2阳性和阴性患者中位生存时间分别为13.8个月与33.9个月，两组比较差异有统计学意义(HR=2.25，95%CI：1.06~4.80，P<0.05)。结论 HER2/c-erbB-2蛋白可能与胃癌的发生发展及侵袭转移有关，并可作为预后不良的分子标志物。